CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter TrialNirali N. Shah, Richard Aplenc, Haneen Shalabi et al.|Blood|2023Cited by 62
Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic MalignanciesMonzr M. Al Malki, Antonio Jimenez Jimenez, Steven M. Devine et al.|Blood|2022Cited by 6
Social Determinants of Health, Disease, and Treatment Related Characteristics of Access Clinical Trial ParticipantsRafeek A. Yusuf, Rachel Cusatis, Eric Ndifon et al.|Transplantation and Cellular Therapy|2024Cited by 1